Abstract
Objective To observe the efficacy of maintenance hormonal treatment after response to chemotherapy in advanced breast cancer. Methods 8 patients with advanced breast cancer were treated with chemotherapy, maintenance hormonal therapy were given after response to chemotherapy. The efficacy was evaluated every 2 cycles of chemotherapy and 2 months of endocrine therapy according to RECIST standard.Results 8 patients received chemotherapy for 2-8 cycles (median 4 cycles). All patients got PR, the duration of chemotherapy was 1-6 months (median 2 months), the time to failure of chemotherapy was 4 months. Until the last follow-up day (31th December 2010), the time to progression was 6-86 months (median 13.5 months).Survival was 6-86 months (median 21.5 months). Seven patients quit the chemotherapy due to severe side effects of hematologic toxicity, fatigue or nausea vomiting. One patient died because of allergy to paclitaxol.Conclusion Maintenance hormonal treatment after patients with metastatic breast cancer response to chemotherapy may prolong the duration of effective therapy and improve the QOL. Key words: Breast neoplasms; Maintenance therapy; Chemotherapy; Endocrine therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
